KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Convertible Debt (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Convertible Debt for 6 consecutive years, with $97.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt rose 0.53% year-over-year to $97.3 million, compared with a TTM value of $97.3 million through Dec 2025, up 0.53%, and an annual FY2025 reading of $97.3 million, up 0.53% over the prior year.
  • Convertible Debt was $97.3 million for Q4 2025 at Esperion Therapeutics, roughly flat from $97.1 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $272.5 million in Q3 2021 and bottomed at $96.7 million in Q4 2024.
  • Average Convertible Debt over 5 years is $221.4 million, with a median of $260.1 million recorded in 2022.
  • The sharpest move saw Convertible Debt soared 44.0% in 2021, then tumbled 63.06% in 2025.
  • Year by year, Convertible Debt stood at $258.3 million in 2021, then increased by 0.63% to $259.9 million in 2022, then increased by 0.65% to $261.6 million in 2023, then plummeted by 63.02% to $96.7 million in 2024, then grew by 0.53% to $97.3 million in 2025.
  • Business Quant data shows Convertible Debt for ESPR at $97.3 million in Q4 2025, $97.1 million in Q3 2025, and $97.0 million in Q2 2025.